| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02117479 Details | 2019-03-26 Interventional | 3 | 321 | Capecitabine Pancreatic Neop… Pancreatic Canc… | The study was terminated early based on the results of the planned interim analysis. The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation at the recommendation of the Data Monitoring Committee. | |||
| NCT01604889 Details | 2019-03-26 Interventional | 1/2 | 136 | Ipilimumab Melanoma | Further development of this compound with ipilimumab in the treatment of melanoma is no longer
being pursued. - | |||
| NCT00498212 Details | 2019-03-26 Interventional | 2 | 41 | 1018 oligonucle… Hepatitis Hepatitis A Hepatitis B Kidney Diseases Kidney Failure,… | Voluntary halt due to an FDA Clinical Hold issued in relation to DV2-HBV-10. - | |||
| NCT00459121 Details | 2019-03-26 Interventional | 2 | 2 | Carboplatin Paclitaxel Carcinoma, Non-… Lung Neoplasms Lung Cancer | - This was a single center study. We did not accrue enough particpants in a timely fashion and a joint decision was made with AstraZeneca to terminate the study. | |||
| NCT00151619 Details | 2019-03-26 Interventional | 2 | 7 | Amlodipine Heart Failure Chronic Heart F… | - - | |||
| NCT03376932 2017-001532-19 Details | 2019-03-25 Interventional | 3 | 0 | Albuterol Tiotropium Brom… Asthma | withdrawn due to internal reasons - | |||
| NCT03221634 2017-001001-32 Details | 2019-03-25 Interventional | 2 | 0 | Daratumumab Pembrolizumab Multiple Myelom… Neoplasms, Plas… | Business Reasons - | |||
| NCT02432066 Details | 2019-03-25 Interventional | 2 | 0 | 3-(2,4-dimethox… Tobacco Use Dis… | Study was not started and participants were not enrolled - | |||
| NCT03021395 Details | 2019-03-22 Interventional | 1/2 | - | Decitabine AML | The previous data needs to be analyzed. - | |||
| NCT01954082 Details | 2019-03-22 Interventional | 3 | 638 | Inositol Premature Birth Retinal Disease… Retinopathy of … Retinopathy of … | Study terminated due to safety concerns; participant follow up will continue until March 2018 Due to a manufacturing issue, enrollment and treatment were temporarily suspended pending review of primary outcome data for the enrolled infants. The statistically significant increase in mortality resulted in early study termination. | |||
| NCT01533376 Details | 2019-03-21 Interventional | 1 | 3 | Lubricant Eye D… Timolol Brain Stem Infa… Klippel-Trenaun… Sturge-Weber Sy… Syndrome Port-wine Mark Sturge Weber Sy… | - - | |||
| NCT02317341 Details | 2019-03-20 Interventional | 1 | 2 | Ketamine Midazolam Fatigue Cancer Ketamine | - - | |||
| NCT01169610 Details | 2019-03-20 Interventional | 3 | 1 | Varenicline Alcoholism Tobacco Use Dis… Nicotine Depend… | - - | |||
| NCT01395537 Details | 2019-03-19 Interventional | 1/2 | 13 | Carboplatin Lapatinib Paclitaxel Adenocarcinoma Esophageal Neop… Adenocarcinoma … Adenocarcinoma … | Research Cancelled One patient was treated in phase II cohort. The study was then prematurely terminated because of the results of the TRIO-013/LOGiC trial. It failed to meet its primary survival endpoint, suggesting little justification for continuation of our study. | |||
| NCT03616639 Details | 2019-03-18 Interventional | 4 | 8 | Morphine Oxycodone Renal Insuffici… Pain Renal Impairmen… Terminal Illnes… | Insufficient inclusion of subjects - | |||
| NCT02472080 Details | 2019-03-18 Interventional | 2 | 21 | Gemcitabine Oxaliplatin Thyroid Disease… Thyroid Neoplas… Thyroid Cancer | inefficiency - | |||
| NCT01907100 2012-005201-48 Details | 2019-03-18 Interventional | 2/3 | 545 | Cisplatin Nintedanib Pemetrexed Mesothelioma Mesothelioma, M… | - In accordance with the specifications in the protocol, the trial was discontinued prematurely after the primary PFS analysis not because of any safety concerns but rather due to failure to meet the efficacy target. | |||
| NCT01209832 2010-020090-16 Details | 2019-03-18 Interventional | 1 | 11 | Midazolam Advanced Cancer | Terminated based on safety results from another trial - | |||
| NCT03278938 Details | 2019-03-15 Interventional | 4 | 0 | Bupropion Citalopram Depression Depressive Diso… Mood Disorders Depressive Illn… | PI Retired and no data was collected - | |||
| NCT02519842 2014-001783-34 Details | 2019-03-15 Interventional | 3 | 75 | Aprepitant Dexamethasone Fosaprepitant Ondansetron Serotonin 5-HT3… Nausea Vomiting Chemotherapy-in… | Further data are no longer required to support an application for use in pediatric patients.
The decision to terminate was not based on any new safety findings Enrollment was terminated early because the data were not necessary to support a claim in pediatric participants and not due to safety concerns. The last participant enrolled on 2016-08-05 and enrolled participants were active until study completion. |